Potentially Dangerous Modifications to E-Cigarettes Common
By Lori Solomon HealthDay Reporter

TUESDAY, July 29, 2025 -- More than eight in 10 electronic cigarette users modify their device, often in potentially dangerous ways, according to a study published online July 9 in Scientific Reports.
Lucy Popova, Ph.D., from Georgia State University in Atlanta, and colleagues evaluated the prevalence of various electronic nicotine delivery systems (ENDS) modifications among U.S. ENDS users. The analysis included responses to a national survey from U.S. youth (13 to 17 years old; 553 respondents), young adults (18 to 29 years old; 634 respondents), and older adults (30 years and older; 760 respondents) who reported past 30-day ENDS use in 2021.
The researchers found that in each age group, a large majority had engaged in at least one ENDS modification (youth, 84.3 percent; young adults, 84.1 percent; and older adults, 76.9 percent). Modifications to e-liquid (68.1, 61.2, and 48.7 percent, respectively) and coils (63.7, 61.4, and 57.2 percent, respectively) were the most common. Some variance in modification prevalence was seen by age group and race/ethnicity. Cited reasons for modifications included accessing or enhancing the flavor of the aerosol. For young adults and older adults, cited reasons included making the device last longer and saving money.
"Many users don’t realize the potential dangers of modifying e-cigarettes," Popova said in a statement. "When people adjust the voltage of a device or add substances to the liquid, they can increase their exposure to harmful chemicals like heavy metals."
One author has disclosed ties to the World Health Organization, Tobacco Free Initiative, and Pfizer.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-07-30 06:00
Read more

- Amgen Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-line Gastric Cancer
- Could Dairy Be Causing Your Bad Dreams?
- The Gut-Healthy Secret Weapon Hiding in Your Sauerkraut
- ENDO: Sweeteners, Genetic Predisposition Independently Linked to Early Puberty
- Regular Sexual Activity Linked to Fewer Genitourinary-Related Symptoms in Menopause
- Measles Outbreak in Kentucky Confirmed
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions